These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

234 related articles for article (PubMed ID: 28011908)

  • 41. Bone mineral density testing, and bisphosphonate and oestrogen prescribing associated with depot medroxyprogesterone acetate utilization-The impact of the boxed warning.
    Eworuke E; Popat V; Moeny DG
    J Clin Pharm Ther; 2017 Aug; 42(4):483-494. PubMed ID: 28543135
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Depot medroxyprogesterone acetate contraception and the risk of breast and gynecologic cancer.
    Kaunitz AM
    J Reprod Med; 1996 May; 41(5 Suppl):419-27. PubMed ID: 8725705
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Hormonal contraception and HIV acquisition risk: implications for individual users and public policies.
    Jain AK
    Contraception; 2012 Dec; 86(6):645-52. PubMed ID: 22541635
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Decline in bone mineral density with stress fractures in a woman on depot medroxyprogesterone acetate. A case report.
    Harkins GJ; Davis GD; Dettori J; Hibbert ML; Hoyt RA
    J Reprod Med; 1999 Mar; 44(3):309-12. PubMed ID: 10202754
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Exogenous oestrogen inhibits genital transmission of cell-associated HIV-1 in DMPA-treated humanized mice.
    Quispe Calla NE; Vicetti Miguel RD; Glick ME; Kwiek JJ; Gabriel JM; Cherpes TL
    J Int AIDS Soc; 2018 Jan; 21(1):. PubMed ID: 29334191
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Repeated administration of high-dose depot medroxyprogesterone acetate does not alter SHIV
    Srinivasan P; Zhang J; Dinh CT; Teller RS; McNicholl JM; Kiser PF; Herold BC; Smith JM
    J Med Primatol; 2017 Aug; 46(4):129-136. PubMed ID: 28748662
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Association between depot medroxyprogesterone acetate (DMPA), physical activity and bone health.
    Babatunde OO; Forsyth JJ
    J Bone Miner Metab; 2014 May; 32(3):305-11. PubMed ID: 23921833
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Depot medroxyprogesterone acetate and breast cancer. A review of current knowledge.
    Chilvers CE
    Drug Saf; 1996 Sep; 15(3):212-8. PubMed ID: 8879975
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Bone mineral density in long-term depot medroxyprogesterone acetate acceptors.
    Taneepanichskul S; Intaraprasert S; Theppisai U; Chaturachinda K
    Contraception; 1997 Jul; 56(1):1-3. PubMed ID: 9306024
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Prevalence of Low Bone Mass and Osteoporosis in Long-Term Users of the Injectable Contraceptive Depot Medroxyprogesterone Acetate.
    Modesto W; Bahamondes MV; Bahamondes L
    J Womens Health (Larchmt); 2015 Aug; 24(8):636-40. PubMed ID: 26098552
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Depot medroxyprogesterone acetate (DMPA) enhances susceptibility and increases the window of vulnerability to HIV-1 in humanized mice.
    Wessels JM; Nguyen PV; Vitali D; Mueller K; Vahedi F; Felker AM; Dupont HA; Bagri P; Verschoor CP; Deshiere A; Mazzulli T; Tremblay MJ; Ashkar AA; Kaushic C
    Sci Rep; 2021 Feb; 11(1):3894. PubMed ID: 33594113
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Interest in self-administration of subcutaneous depot medroxyprogesterone acetate in the United States.
    Upadhyay UD; Zlidar VM; Foster DG
    Contraception; 2016 Oct; 94(4):303-13. PubMed ID: 27326938
    [TBL] [Abstract][Full Text] [Related]  

  • 53. A Depot Medroxyprogesterone Acetate Dose That Models Human Use and Its Effect on Vaginal SHIV Acquisition Risk.
    Butler K; Ritter JM; Ellis S; Morris MR; Hanson DL; McNicholl JM; Kersh EN
    J Acquir Immune Defic Syndr; 2016 Aug; 72(4):363-71. PubMed ID: 27355414
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Analysis of putative mucosal SHIV susceptibility factors during repeated DMPA treatments in pigtail macaques.
    Butler K; Ritter J; Ellis S; Henning TR; Montague J; Zaki S; Garber D; McNicholl JM; Kersh EN
    J Med Primatol; 2015 Oct; 44(5):286-95. PubMed ID: 26238265
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Medroxyprogesterone acetate alters the vaginal microbiota and microenvironment in women and increases susceptibility to HIV-1 in humanized mice.
    Wessels JM; Lajoie J; Cooper MIJH; Omollo K; Felker AM; Vitali D; Dupont HA; Nguyen PV; Mueller K; Vahedi F; Kimani J; Oyugi J; Cheruiyot J; Mungai JN; Deshiere A; Tremblay MJ; Mazzulli T; Stearns JC; Ashkar AA; Fowke KR; Surette MG; Kaushic C
    Dis Model Mech; 2019 Oct; 12(10):. PubMed ID: 31537512
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Hormonal contraception decreases bacterial vaginosis but oral contraception may increase candidiasis: implications for HIV transmission.
    van de Wijgert JH; Verwijs MC; Turner AN; Morrison CS
    AIDS; 2013 Aug; 27(13):2141-53. PubMed ID: 23660575
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Preexposure prophylaxis is efficacious for HIV-1 prevention among women using depot medroxyprogesterone acetate for contraception.
    Heffron R; Mugo N; Were E; Kiarie J; Bukusi EA; Mujugira A; Frenkel LM; Donnell D; Ronald A; Celum C; Baeten JM;
    AIDS; 2014 Nov; 28(18):2771-6. PubMed ID: 25493602
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Clinical evaluation of the therapeutic effectiveness of ethinyl oestradiol and oestrone sulphate on prolonged bleeding in women using depot medroxyprogesterone acetate for contraception. World Health Organization, Special Programme of Research, Development and Research Training in Human Reproduction, Task Force on Long-acting Systemic Agents for Fertility Regulation.
    Said S; Sadek W; Rocca M; Koetsawang S; Kirwat O; Piya-Anant M; Dusitsin N; Sethavanich S; Affandi B; Hadisaputra W; Kazi A; Ramos RM; d'Arcangues C; Belsey EM; Noonan E; Olayinka I; Pinol A
    Hum Reprod; 1996 Oct; 11 Suppl 2():1-13. PubMed ID: 8982739
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Body weight and body composition of depot medroxyprogesterone acetate users.
    Dal'Ava N; Bahamondes L; Bahamondes MV; Bottura BF; Monteiro I
    Contraception; 2014 Aug; 90(2):182-7. PubMed ID: 24780631
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Bone density in women receiving depot medroxyprogesterone acetate for contraception.
    Cundy T; Evans M; Roberts H; Wattie D; Ames R; Reid IR
    BMJ; 1991 Jul; 303(6793):13-6. PubMed ID: 1830502
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.